PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany. ehrenreich@em.mpg.de.\', \'Department of Neurology, Hannover Medical School, Hannover, Germany.\', \'Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany.\', \'Department of Psychiatry & Psychotherapy, University Medical Center, Göttingen, Germany.\', \'Center of Internal Medicine, Hannover Medical School, Hannover, Germany.\', \'Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Spain.\', \'Psychiatric Centre Copenhagen, University Hospital, Rigshospitalet, Copenhagen, Denmark. Kamilla.miskowiak@regionh.dk.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1186/s10020-020-00186-y
?:hasPublicationType
?:journal
  • Molecular medicine (Cambridge, Mass.)
is ?:pmid of
?:pmid
?:pmid
  • 32546125
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
?:title
  • Erythropoietin as candidate for supportive treatment of severe COVID-19.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all